13 results on '"Macías-Valcayo, Alicia"'
Number of results to display per page
Search Results
2. Synovial Fluid Mediated Aggregation of Clinical Strains of Four Enterobacterial Species
- Author
-
Macias-Valcayo, Alicia, Staats, Amelia, Aguilera-Correa, John-Jairo, Brooks, Jack, Gupta, Tripti, Dusane, Devendra, Stoodley, Paul, Esteban, Jaime, Crusio, Wim E., Series Editor, Dong, Haidong, Series Editor, Radeke, Heinfried H., Series Editor, Rezaei, Nima, Series Editor, Steinlein, Ortrud, Series Editor, Xiao, Junjie, Series Editor, and Donelli, Gianfranco, editor
- Published
- 2021
- Full Text
- View/download PDF
3. Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia
- Author
-
Górgolas Hernández-Mora, Miguel, Cabello Úbeda, Alfonso, Prieto-Pérez, Laura, Villar Álvarez, Felipe, Álvarez Álvarez, Beatriz, Rodríguez Nieto, María Jesús, Carrillo Acosta, Irene, Fernández Ormaechea, Itziar, Al-Hayani, Aws Waleed Mohammed, Carballosa, Pilar, Calpena Martínez, Silvia, Ezzine, Farah, Castellanos González, Marina, Naya, Alba, López De Las Heras, Marta, Rodríguez Guzmán, Marcel José, Cordero Guijarro, Ana, Broncano Lavado, Antonio, Macías Valcayo, Alicia, Martín García, Marta, Bécares Martínez, Javier, Fernández Roblas, Ricardo, Piris Pinilla, Miguel Ángel, Fortes Alen, José, Sánchez Pernaute, Olga, Romero Bueno, Fredeswinda, Heili-Frades, Sarah, and Peces-Barba Romero, Germán
- Published
- 2021
- Full Text
- View/download PDF
4. High SARS-CoV-2 viral load is associated with a worse clinical outcome of COVID-19 disease
- Author
-
Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades (España), European Commission, Consejo Superior de Investigaciones Científicas (España), Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (España), Fundación Ramón Areces, Fundación Banco Santander, Agencia Estatal de Investigación (España), Comunidad de Madrid, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Soria, María Eugenia [0000-0002-4719-3351], Cortón, Marta [0000-0003-0087-1626], Martínez-González, Brenda [0000-0002-4482-5181], Lobo-Vega, Rebeca [0000-0002-4882-6763], Vázquez-Sirvent, Lucía [0000-0002-0396-7781], Mínguez, Pablo [0000-0003-4099-9421], Macías-Valcayo, Alicia [0000-0003-3879-0493], Esteban, Jaime [0000-0002-8971-3167], Gadea, Ignacio [0000-0003-4684-7816], Ayuso, Carmen [0000-0002-9242-7065], Perales, Celia [000-0003-1618-1937], Soria, María Eugenia, Cortón, Marta, Martínez-González, Brenda, Lobo-Vega, Rebeca, Vázquez-Sirvent, Lucía, López-Rodríguez, Rosario, Almoguera, Berta, Mahillo-Fernández, Ignacio, Mínguez, Pablo, Herrero, Antonio, Taracido, Juan Carlos, Macías-Valcayo, Alicia, Esteban, Jaime, Fernández-Roblas, Ricardo, Gadea, Ignacio, Ruíz-Hornillos, Javier, Ayuso, Carmen, Perales, Celia, Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades (España), European Commission, Consejo Superior de Investigaciones Científicas (España), Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (España), Fundación Ramón Areces, Fundación Banco Santander, Agencia Estatal de Investigación (España), Comunidad de Madrid, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Soria, María Eugenia [0000-0002-4719-3351], Cortón, Marta [0000-0003-0087-1626], Martínez-González, Brenda [0000-0002-4482-5181], Lobo-Vega, Rebeca [0000-0002-4882-6763], Vázquez-Sirvent, Lucía [0000-0002-0396-7781], Mínguez, Pablo [0000-0003-4099-9421], Macías-Valcayo, Alicia [0000-0003-3879-0493], Esteban, Jaime [0000-0002-8971-3167], Gadea, Ignacio [0000-0003-4684-7816], Ayuso, Carmen [0000-0002-9242-7065], Perales, Celia [000-0003-1618-1937], Soria, María Eugenia, Cortón, Marta, Martínez-González, Brenda, Lobo-Vega, Rebeca, Vázquez-Sirvent, Lucía, López-Rodríguez, Rosario, Almoguera, Berta, Mahillo-Fernández, Ignacio, Mínguez, Pablo, Herrero, Antonio, Taracido, Juan Carlos, Macías-Valcayo, Alicia, Esteban, Jaime, Fernández-Roblas, Ricardo, Gadea, Ignacio, Ruíz-Hornillos, Javier, Ayuso, Carmen, and Perales, Celia
- Abstract
COVID-19 severity and progression are determined by several host and virological factors that may influence the final outcome of SARS-CoV-2-infected patients. The objective of this work was to determine a possible association between viral load, obtained from nasopharyngeal swabs, and the severity of the infection in a cohort of 448 SARS-CoV-2-infected patients from a hospital in Madrid during the first outbreak of the pandemic in Spain. To perform this, we clinically classified patients as mild, moderate and severe COVID-19 according to a number of clinical parameters such as hospitalization requirement, need of oxygen therapy, admission to intensive care units and/or death. Also, Ct values were determined using SARS-CoV-2-specific oligonucleotides directed to ORF1ab. Here we report a statistically significant association between viral load and disease severity, a high viral load being associated with worse clinical prognosis, independently of several previously identified risk factors such as age, sex, hypertension, cardiovascular disease, diabetes, obesity and lung disease (asthma and chronic obstructive pulmonary disease). The data presented here reinforce viral load as a potential biomarker for predicting disease severity in SARS-CoV-2-infected patients. It is also an important parameter in viral evolution since it relates to the numbers and types of variant genomes present in a viral population, a potential determinant of disease progression.
- Published
- 2021
5. High SARS-CoV-2 viral load is associated with a worse clinical outcome of COVID-19 disease
- Author
-
Soria, María Eugenia, primary, Cortón, Marta, additional, Martínez-González, Brenda, additional, Lobo-Vega, Rebeca, additional, Vázquez-Sirvent, Lucía, additional, López-Rodríguez, Rosario, additional, Almoguera, Berta, additional, Mahillo, Ignacio, additional, Mínguez, Pablo, additional, Herrero, Antonio, additional, Taracido, Juan Carlos, additional, Macías-Valcayo, Alicia, additional, Esteban, Jaime, additional, Fernandez-Roblas, Ricardo, additional, Gadea, Ignacio, additional, Ruíz-Hornillos, Javier, additional, Ayuso, Carmen, additional, and Perales, Celia, additional
- Published
- 2021
- Full Text
- View/download PDF
6. High SARS-CoV-2 viral load is associated with a worse clinical outcome of COVID-19 disease
- Author
-
Soria, María Eugenia, primary, Cortón, Marta, additional, Martínez-González, Brenda, additional, Lobo-Vega, Rebeca, additional, Vázquez-Sirvent, Lucía, additional, López-Rodríguez, Rosario, additional, Almoguera, Berta, additional, Mahillo, Ignacio, additional, Mínguez, Pablo, additional, Herrero, Antonio, additional, Taracido, Juan Carlos, additional, Macías-Valcayo, Alicia, additional, Esteban, Jaime, additional, Fernandez-Roblas, Ricardo, additional, Gadea, Ignacio, additional, Ruíz-Hornillos, Javier, additional, Ayuso, Carmen, additional, and Perales, Celia, additional
- Published
- 2020
- Full Text
- View/download PDF
7. High SARS-CoV-2 viral load is associated with a worse clinical outcome of COVID-19 disease
- Author
-
Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), European Commission, Consejo Superior de Investigaciones Científicas (España), Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (España), Fundación Ramón Areces, Banco Santander, Comunidad de Madrid, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Soria, María Eugenia [0000-0002-4719-3351], Lobo-Vega, Rebeca [0000-0002-4882-6763], Perales, Celia [0000-0003-1618-1937], Soria, María Eugenia, Cortón, Marta, Martínez-González, Brenda, Lobo-Vega, Rebeca, Vázquez-Sirvent, Lucía, López-Rodríguez, Rosario, Almoguera, Berta, Mahillo-Fernández, Ignacio, Mínguez, Pablo, Herrero, Antonio, Taracido, Juan Carlos, Macías-Valcayo, Alicia, Esteban, Jaime, Fernández-Roblas, Ricardo, Gadea, Ignacio, Ruíz-Hornillos, Javier, Ayuso, Carmen, Perales, Celia, Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), European Commission, Consejo Superior de Investigaciones Científicas (España), Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (España), Fundación Ramón Areces, Banco Santander, Comunidad de Madrid, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Soria, María Eugenia [0000-0002-4719-3351], Lobo-Vega, Rebeca [0000-0002-4882-6763], Perales, Celia [0000-0003-1618-1937], Soria, María Eugenia, Cortón, Marta, Martínez-González, Brenda, Lobo-Vega, Rebeca, Vázquez-Sirvent, Lucía, López-Rodríguez, Rosario, Almoguera, Berta, Mahillo-Fernández, Ignacio, Mínguez, Pablo, Herrero, Antonio, Taracido, Juan Carlos, Macías-Valcayo, Alicia, Esteban, Jaime, Fernández-Roblas, Ricardo, Gadea, Ignacio, Ruíz-Hornillos, Javier, Ayuso, Carmen, and Perales, Celia
- Abstract
COVID-19 severity and progression are determined by several host and virological factors that may influence the final outcome of SARS-CoV-2-infected patients. The objective of this work is to determine a possible association between the viral load, obtained from nasopharyngeal swabs, and the severity of the infection in a cohort of 448 SARS-CoV-2-infected patients from a hospital in Madrid during the first outbreak of the pandemic in Spain. To perform this, we have clinically classified patients as mild, moderate and severe COVID-19 according to a number of clinical parameters such as hospitalization requirement, need of oxygen therapy, admission to intensive care units and/or exitus. Here we report a statistically significant correlation between viral load and disease severity, being high viral load associated with worse clinical prognosis, independently of several previously identified risk factors such as age, sex, hypertension, cardiovascular disease, diabetes, obesity, and lung disease (asthma and chronic obstructive pulmonary disease). The data presented here reinforce the viral load as a potential biomarker for predicting disease severity in SARS-CoV-2-infected patients. It is also an important parameter in viral evolution since it relates to the numbers and types of variant genomes present in a viral population, a potential determinant of disease progression.
- Published
- 2020
8. Orthopedic Implant-Associated Infection by Multidrug Resistant Enterobacteriaceae
- Author
-
Pfang, Bernadette G., primary, García-Cañete, Joaquín, additional, García-Lasheras, Julia, additional, Blanco, Antonio, additional, Auñón, Álvaro, additional, Parron-Cambero, Raul, additional, Macías-Valcayo, Alicia, additional, and Esteban, Jaime, additional
- Published
- 2019
- Full Text
- View/download PDF
9. Optimización del uso deantipsicóticos en esquizofrenia
- Author
-
Díaz Pires, Antonio David, García Aldana, Irene, Macías Valcayo, Alicia, Ruiz Díaz, Jennifer, and Gonzalez Prieto, Pilar
- Subjects
Farmacología ,Psiquiatría - Abstract
The Canadian Agency for Drugs and Technologies in Health (CADTH) ha publicado un informe sobre recomendaciones para hacer un uso óptimo de los antipsicóticos atípicos en cuanto a dosis y asociaciones en esquizofrenia o trastornos esquizoafectivos. Se realiza un estudio observacional transversal en un hospital psiquiátrico en 110 pacientes de sexo femenino, de la unidad de larga estancia, con diagnóstico de esquizofrenia y sus diferentes subtipos. Se estudia la coexistencia de fármacos pertenecientes al grupo NO5A antipsicóticos según clasificación ATC, recogiéndose dosis y número de fármacos. Se estudia la comorbilidad de otros patologías por el consumo de fármacos pertenecientes a los grupos A06 laxantes y grupo N04 antiparkinsonianos según clasificación ATC, como grupos secundarios al tratamiento antipicóticos.
- Published
- 2014
10. Optimización del uso deantipsicóticos en esquizofrenia
- Author
-
Gonzalez Prieto, Pilar, Díaz Pires, Antonio David, García Aldana, Irene, Macías Valcayo, Alicia, Ruiz Díaz, Jennifer, Gonzalez Prieto, Pilar, Díaz Pires, Antonio David, García Aldana, Irene, Macías Valcayo, Alicia, and Ruiz Díaz, Jennifer
- Abstract
The Canadian Agency for Drugs and Technologies in Health (CADTH) ha publicado un informe sobre recomendaciones para hacer un uso óptimo de los antipsicóticos atípicos en cuanto a dosis y asociaciones en esquizofrenia o trastornos esquizoafectivos. Se realiza un estudio observacional transversal en un hospital psiquiátrico en 110 pacientes de sexo femenino, de la unidad de larga estancia, con diagnóstico de esquizofrenia y sus diferentes subtipos. Se estudia la coexistencia de fármacos pertenecientes al grupo NO5A antipsicóticos según clasificación ATC, recogiéndose dosis y número de fármacos. Se estudia la comorbilidad de otros patologías por el consumo de fármacos pertenecientes a los grupos A06 laxantes y grupo N04 antiparkinsonianos según clasificación ATC, como grupos secundarios al tratamiento antipicóticos.
- Published
- 2014
11. Epidemiology and in vitroantimicrobial susceptibility of aerobic Actinomycetales in a clinical setting
- Author
-
Salar-Vidal, Llanos, Martín-García, Marta, Macías-Valcayo, Alicia, Ponz, Ana, and Esteban, Jaime
- Abstract
The incidence of infections caused by aerobic actinomycetes is increasing. Recent changes in taxonomy and the variability in susceptibility patterns among species make necessary a proper identification and antibiotic susceptibility testing.
- Published
- 2021
- Full Text
- View/download PDF
12. High SARS-CoV-2 viral load is associated with a worse clinical outcome of COVID-19 disease
- Author
-
Ignacio Gadea, Javier Ruiz-Hornillos, Rebeca Lobo-Vega, Jaime Esteban, Carmen Ayuso, A. Herrero, Marta Corton, Juan Carlos Taracido, Pablo Minguez, Ricardo Fernández-Roblas, Rosario López-Rodríguez, Ignacio Mahillo, María Eugenia Soria, Alicia Macías-Valcayo, Berta Almoguera, Lucía Vázquez-Sirvent, Brenda Martínez-González, Celia Perales, Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades (España), European Commission, Consejo Superior de Investigaciones Científicas (España), Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (España), Fundación Ramón Areces, Fundación Banco Santander, Agencia Estatal de Investigación (España), Comunidad de Madrid, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Soria, María Eugenia [0000-0002-4719-3351], Cortón, Marta [0000-0003-0087-1626], Martínez-González, Brenda [0000-0002-4482-5181], Lobo-Vega, Rebeca [0000-0002-4882-6763], Vázquez-Sirvent, Lucía [0000-0002-0396-7781], Mínguez, Pablo [0000-0003-4099-9421], Macías-Valcayo, Alicia [0000-0003-3879-0493], Esteban, Jaime [0000-0002-8971-3167], Gadea, Ignacio [0000-0003-4684-7816], Ayuso, Carmen [0000-0002-9242-7065], Perales, Celia [000-0003-1618-1937], Banco Santander, Perales, Celia [0000-0003-1618-1937], Soria, María Eugenia, Lobo-Vega, Rebeca, Perales, Celia, Cortón, Marta, Martínez-González, Brenda, Vázquez-Sirvent, Lucía, Mínguez, Pablo, Macías-Valcayo, Alicia, Esteban, Jaime, Gadea, Ignacio, and Ayuso, Carmen
- Subjects
medicine.medical_specialty ,education.field_of_study ,business.industry ,viruses ,Population ,Short Communications ,Outbreak ,COVID-19 ,Disease ,medicine.disease ,viral load ,Risk factors ,Diabetes mellitus ,Intensive care ,Internal medicine ,Cohort ,medicine ,risk factors ,General Materials Science ,Viral load ,education ,business ,Asthma - Abstract
Publisher's version disponible en: http://hdl.handle.net/10261/257116, COVID-19 severity and progression are determined by several host and virological factors that may influence the final outcome of SARS-CoV-2-infected patients. The objective of this work is to determine a possible association between the viral load, obtained from nasopharyngeal swabs, and the severity of the infection in a cohort of 448 SARS-CoV-2-infected patients from a hospital in Madrid during the first outbreak of the pandemic in Spain. To perform this, we have clinically classified patients as mild, moderate and severe COVID-19 according to a number of clinical parameters such as hospitalization requirement, need of oxygen therapy, admission to intensive care units and/or exitus. Here we report a statistically significant correlation between viral load and disease severity, being high viral load associated with worse clinical prognosis, independently of several previously identified risk factors such as age, sex, hypertension, cardiovascular disease, diabetes, obesity, and lung disease (asthma and chronic obstructive pulmonary disease). The data presented here reinforce the viral load as a potential biomarker for predicting disease severity in SARS-CoV-2-infected patients. It is also an important parameter in viral evolution since it relates to the numbers and types of variant genomes present in a viral population, a potential determinant of disease progression., This work was supported by Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (COVID-19 Research Call COV20/00181) co-financed by European Development Regional Fund (A way to achieve Europe). The work was also supported by grants CSIC-COV19-014 from Consejo Superior de Investigaciones Cientificas (CSIC), BFU2017-91384-EXP from Ministerio de Ciencia, Innovacion y Universidades (MICIU), PI18/00210 from Instituto de Salud Carlos III. C.P., M.C. and P.M. are supported by the Miguel Servet program of the Instituto de Salud Carlos III (CPII19/00001, CPII17/00006 and CP16/00116, respectively) cofinanced by the European Regional Development Fund (ERDF). CIBERehd (Centro de Investigacion en Red de Enfermedades Hepaticas y Digestivas) is funded by Instituto de Salud Carlos III. Institutional grants from the Fundacion Ramon Areces and Banco Santander to the CBMSO are also acknowledged. The team at CBMSO belongs to the Global Virus Network (GVN). B. M.-G. is supported by predoctoral contract PFIS FI19/00119 from Instituto de Salud Carlos III (Ministerio de Sanidad y Consumo) cofinanced by Fondo Social Europeo (FSE). R. L.-V. is supported by predoctoral contract PEJD-2019-PRE/BMD-16414 from Comunidad de Madrid. R L-R is sponsored by the IIS-Fundacion Jimenez Diaz-UAM Genomic Medicine Chair.
- Published
- 2021
13. Epidemiology and in vitro antimicrobial susceptibility of aerobic Actinomycetales in a clinical setting.
- Author
-
Salar-Vidal L, Martín-García M, Macías-Valcayo A, Ponz A, and Esteban J
- Abstract
Introduction: The incidence of infections caused by aerobic actinomycetes is increasing. Recent changes in taxonomy and the variability in susceptibility patterns among species make necessary a proper identification and antibiotic susceptibility testing., Material and Methods: Fifty-three strains of aerobic actinomycetes were identified by MALDI-TOF MS using the VITEK MS Mycobacterium/Nocardia kit (bioMérieux, France) in a tertiary hospital in Spain during a six-year period. Antimicrobial susceptibility testing of the isolates was performed using the Sensititre Rapmycoi microdilution panel (Thermo Fisher Scientific, Massachusetts, USA)., Results: Forty strains of Nocardia spp. were identified in the study, being N. farcinica and N. cyriacigeorgica the most prevalent ones. All isolates were susceptible to linezolid and the resistance to amikacin was only observed in one isolate of Gordonia sputi. Resistance to cotrimoxazole was only found in five isolates., Conclusions: Routine identification and antimicrobial susceptibility testing of aerobic actinomycetes is advisable for an efficient identification of species and effective treatment., (Copyright © 2021 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.